Ligand Pharmaceuticals (LGND) has received a significantly revised average one-year price target of $232.69/share, marking a 24.57% increase from the prior estimate and suggesting a 15.85% upside from its latest closing price. This upward revision coincides with a notable increase in institutional interest, as 645 funds now report positions—a 6.97% rise in owners and a 6.58% increase in total institutional shares over the last quarter—further supported by a bullish put/call ratio of 0.46.
Ligand Pharmaceuticals (LGND) has received a significant upward revision in its average one-year price target to $232.69 per share, representing a 24.57% increase from the prior estimate of $186.79. This new target implies a 15.85% upside from the latest closing price of $200.86, reflecting a strong positive outlook from the analyst community, with targets ranging from $176.75 to $288.75. Institutional interest in LGND has notably increased, with 645 funds now reporting positions, marking a 6.97% rise in owners over the last quarter. Total shares owned by institutions grew by 6.58% to 28,143K shares, and the average portfolio weight dedicated to LGND increased by 6.62% to 0.25%, signaling broad-based accumulation. Despite the overall positive institutional trend, specific large shareholders exhibit mixed activity; Congress Asset Management increased its portfolio allocation by 55.69%, while Janus Henderson Group and Macquarie Group significantly decreased theirs by 45.04% and 47.44% respectively. However, the put/call ratio of 0.46 reinforces a bullish sentiment among options traders, aligning with the upward price target revision and overall institutional accumulation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment
